Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings (MEDP) is a leading global clinical research organization accelerating drug development through full-service trial management. This page provides investors and industry professionals with timely updates on MEDP's clinical trial milestones, regulatory developments, and strategic partnerships.
Access official press releases and curated analysis covering key operational areas including therapeutic research advancements, bioanalytical innovations, and global trial management. Our repository ensures transparent tracking of MEDP's progress in oncology, cardiology, and rare disease research sectors.
Discover updates across critical categories: quarterly financial results, FDA submission announcements, international trial initiations, and executive leadership changes. All content is verified through primary sources to maintain accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of MEDP's role in advancing clinical research. For real-time updates, consider enabling notifications or subscribing to our institutional research alerts.
Medpace Holdings, Inc. (MEDP) reported strong financial results for Q2 2024. Revenue increased 14.6% to $528.1 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $88.4 million, or $2.75 per diluted share, up from $61.1 million in Q2 2023. The company's net income margin improved to 16.7%, while EBITDA grew 34.2% to $112.3 million.
Medpace's backlog increased 13.7% to $2,924.9 million, and net new business awards were $551.0 million, resulting in a net book-to-bill ratio of 1.04x. The company updated its 2024 financial guidance, forecasting revenue between $2.125 billion and $2.175 billion, representing 12.7% to 15.3% growth over 2023.
Medpace Holdings will announce its Q2 2024 financial results post-market on July 22, 2024.
A conference call to discuss the results is scheduled for July 23, 2024, at 9:00 a.m. ET.
Participants must register in advance via a provided link, and step-by-step access details will be sent by email.
The call can also be accessed through a webcast on Medpace's investor site, where a replay and supplemental slide presentation will be available post-call.
Medpace is traded under the ticker MEDP on Nasdaq.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
